Jardiance Under Review for CKD; Frailty in Obesity; DIY Semaglutide?
(MedPage Today) -- The FDA is reviewing a potential new indication for empagliflozin (Jardiance) for risk reduction of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD) based on the EMPA-KIDNEY phase...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Eating Disorders & Weight Management | Empagliflozin | Endocrinology | Heart | Jardiance | Obesity | Urology & Nephrology